Skip to content

Alumis Inc. ALMS Market capitalization

Market capitalization at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$123.83B-0.2%
Amgen logo
AmgenAMGN
$189.67B+13.3%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.43B+533%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$2.11B+75.2%
Vera Therapeutics logo
Vera TherapeuticsVERA
$2.87B+87.5%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$4.44B+662%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Computed from the period-end share price: $2.8B.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s market capitalization?
Alumis Inc. (ALMS) reported market capitalization of $2.8B in Q1 2026.
How has Alumis Inc.'s market capitalization changed year-over-year?
Alumis Inc.'s market capitalization increased by 738.8% year-over-year, from $334.06M to $2.8B.
What does market capitalization mean?
The total market value of the company's equity at the quarter end (share price × shares outstanding), sampled from daily market data. The latest point tracks the live price.